279 related articles for article (PubMed ID: 29317734)
1. Combined SEP and anti-PD-L1 antibody produces a synergistic antitumor effect in B16-F10 melanoma-bearing mice.
Hu Z; Ye L; Xing Y; Hu J; Xi T
Sci Rep; 2018 Jan; 8(1):217. PubMed ID: 29317734
[TBL] [Abstract][Full Text] [Related]
2. An Immunomodulatory Gallotanin-Rich Fraction From
Lasso P; Gomez-Cadena A; Urueña C; Donda A; Martinez-Usatorre A; Romero P; Barreto A; Fiorentino S
Front Immunol; 2020; 11():584959. PubMed ID: 33312174
[TBL] [Abstract][Full Text] [Related]
3. PCC0208025 (BMS202), a small molecule inhibitor of PD-L1, produces an antitumor effect in B16-F10 melanoma-bearing mice.
Hu Z; Yu P; Du G; Wang W; Zhu H; Li N; Zhao H; Dong Z; Ye L; Tian J
PLoS One; 2020; 15(3):e0228339. PubMed ID: 32214351
[TBL] [Abstract][Full Text] [Related]
4. Novel Treatment of Melanoma: Combined Parasite-Derived Peptide GK-1 and Anti-Programmed Death Ligand 1 Therapy.
Vera-Aguilera J; Perez-Torres A; Beltran D; Villanueva-Ramos C; Wachtel M; Moreno-Aguilera E; Vera-Aguilera C; Ventolini G; Martínez-Zaguilán R; Sennoune SR
Cancer Biother Radiopharm; 2017 Mar; 32(2):49-56. PubMed ID: 28301259
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant effect of the novel TLR1/TLR2 agonist Diprovocim synergizes with anti-PD-L1 to eliminate melanoma in mice.
Wang Y; Su L; Morin MD; Jones BT; Mifune Y; Shi H; Wang KW; Zhan X; Liu A; Wang J; Li X; Tang M; Ludwig S; Hildebrand S; Zhou K; Siegwart DJ; Moresco EMY; Zhang H; Boger DL; Beutler B
Proc Natl Acad Sci U S A; 2018 Sep; 115(37):E8698-E8706. PubMed ID: 30150374
[TBL] [Abstract][Full Text] [Related]
6. Augmentation of Immune Checkpoint Cancer Immunotherapy with IL18.
Ma Z; Li W; Yoshiya S; Xu Y; Hata M; El-Darawish Y; Markova T; Yamanishi K; Yamanishi H; Tahara H; Tanaka Y; Okamura H
Clin Cancer Res; 2016 Jun; 22(12):2969-80. PubMed ID: 26755531
[TBL] [Abstract][Full Text] [Related]
7. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
Guo Z; Wang H; Meng F; Li J; Zhang S
J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551
[TBL] [Abstract][Full Text] [Related]
8. CD122-targeted interleukin-2 and αPD-L1 treat bladder cancer and melanoma via distinct mechanisms, including CD122-driven natural killer cell maturation.
Reyes RM; Zhang C; Deng Y; Ji N; Mukherjee N; Padron AS; Clark CA; Svatek RS; Curiel TJ
Oncoimmunology; 2021; 10(1):2006529. PubMed ID: 34858732
[TBL] [Abstract][Full Text] [Related]
9. Intratumoral injection of IFN-β induces chemokine production in melanoma and augments the therapeutic efficacy of anti-PD-L1 mAb.
Uehara J; Ohkuri T; Kosaka A; Ishibashi K; Hirata Y; Ohara K; Nagato T; Oikawa K; Aoki N; Harabuchi Y; Ishida-Yamamoto A; Kobayashi H
Biochem Biophys Res Commun; 2017 Aug; 490(2):521-527. PubMed ID: 28624449
[TBL] [Abstract][Full Text] [Related]
10. B16 melanoma control by anti-PD-L1 requires CD8+ T cells and NK cells: application of anti-PD-L1 Abs and Trp2 peptide vaccines.
Ji S; Lee J; Lee ES; Kim DH; Sin JI
Hum Vaccin Immunother; 2021 Jul; 17(7):1910-1922. PubMed ID: 33522416
[TBL] [Abstract][Full Text] [Related]
11. Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma.
Pilon-Thomas S; Mackay A; Vohra N; Mulé JJ
J Immunol; 2010 Apr; 184(7):3442-9. PubMed ID: 20194714
[TBL] [Abstract][Full Text] [Related]
12. Ultrasound targeting of microbubble-bound anti PD-L1 mAb to enhance anti-tumor effect of cisplatin in cervical cancer xenografts treatment.
Ma Y; Han J; Jiang J; Zheng Z; Tan Y; Liu C; Zhao Y
Life Sci; 2020 Dec; 262():118565. PubMed ID: 33038371
[TBL] [Abstract][Full Text] [Related]
13. NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation.
Xu D; Gu P; Pan PY; Li Q; Sato AI; Chen SH
Int J Cancer; 2004 Apr; 109(4):499-506. PubMed ID: 14991570
[TBL] [Abstract][Full Text] [Related]
14. Radiation improves antitumor effect of immune checkpoint inhibitor in murine hepatocellular carcinoma model.
Kim KJ; Kim JH; Lee SJ; Lee EJ; Shin EC; Seong J
Oncotarget; 2017 Jun; 8(25):41242-41255. PubMed ID: 28465485
[TBL] [Abstract][Full Text] [Related]
15. PET imaging facilitates antibody screening for synergistic radioimmunotherapy with a
Ren J; Xu M; Chen J; Ding J; Wang P; Huo L; Li F; Liu Z
Theranostics; 2021; 11(1):304-315. PubMed ID: 33391476
[No Abstract] [Full Text] [Related]
16. CD122-directed interleukin-2 treatment mechanisms in bladder cancer differ from αPD-L1 and include tissue-selective γδ T cell activation.
Reyes RM; Deng Y; Zhang D; Ji N; Mukherjee N; Wheeler K; Gupta HB; Padron AS; Kancharla A; Zhang C; Garcia M; Kornepati AVR; Boyman O; Conejo-Garcia JR; Svatek RS; Curiel TJ
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33849925
[TBL] [Abstract][Full Text] [Related]
17. Enhancing CTL responses to melanoma cell vaccines in vivo: synergistic increases obtained using IFNgamma primed and IFNbeta treated B7-1+ B16-F10 melanoma cells.
Dezfouli S; Hatzinisiriou I; Ralph SJ
Immunol Cell Biol; 2003 Dec; 81(6):459-71. PubMed ID: 14636243
[TBL] [Abstract][Full Text] [Related]
18. Synergistic antitumor effects of CpG oligodeoxynucleotide and STAT3 inhibitory agent JSI-124 in a mouse melanoma tumor model.
Molavi O; Ma Z; Hamdy S; Lai R; Lavasanifar A; Samuel J
Immunol Cell Biol; 2008; 86(6):506-14. PubMed ID: 18392040
[TBL] [Abstract][Full Text] [Related]
19. Dual activity of PD-L1 targeted Doxorubicin immunoliposomes promoted an enhanced efficacy of the antitumor immune response in melanoma murine model.
Merino M; Lozano T; Casares N; Lana H; Troconiz IF; Ten Hagen TLM; Kochan G; Berraondo P; Zalba S; Garrido MJ
J Nanobiotechnology; 2021 Apr; 19(1):102. PubMed ID: 33849551
[TBL] [Abstract][Full Text] [Related]
20. A novel form of immunotherapy using antigen peptides conjugated on PD-L1 antibody.
Lee EJ; Jang GY; Lee SE; Lee JW; Han HD; Park YM; Kang TH
Immunol Lett; 2021 Dec; 240():137-148. PubMed ID: 34710507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
